Hemochromatosis medical therapy

Jump to navigation Jump to search

Hemochromatosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemochromatosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemochromatosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemochromatosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemochromatosis medical therapy

CDC on Hemochromatosis medical therapy

Hemochromatosis medical therapy in the news

Blogs on Hemochromatosis medical therapy

Directions to Hospitals Treating Hemochromatosis

Risk calculators and risk factors for Hemochromatosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]

Overview

The treatment of hemochromatosis depends on levels of iron deposition in body tissues, symptoms and complications due to damaged organs secondary to inflammatory response towards deposition.

Medical Therapy

  • Treatment is initiated when ferritin levels reach 300 micrograms per litre (or 200 in nonpregnant premenopausal women).
  • Treatment of organ damage (heart failure with diuretics and ACE inhibitor therapy).
  • Limiting intake of alcoholic beverages, vitamin C (increases iron absorption in the gut), red meat (high in iron) and potential causes of food poisoning (shellfish, seafood).
  • Increasing intake of substances that inhibit iron absorption, such as high-tannin tea, calcium, and foods containing oxalic and phytic acids (these must be consumed at the same time as the iron-containing foods in order to be effective.

Following are the recommendations for treating hemochromatosis according to American Association for the Study of Liver Diseases:

Phlebotomy is recommended option for the patients with iron over load weather they are symptomatic or not.[1][2][3][4]

1 Starting therapeutic phlebotomy: Staring blood removal till iron level gets normal.

  • 1.1 Asymptomatic hemochromatosis:
  • Preferred regime: 1 unit of blood (about 473 mL or 1 pint) is removed per week
  • Alternative regime: 0.5 to 2 units of blood can often be removed from men, whereas it may be possible to remove only 0.5 units of blood from women or frail or elderly patients with other medical problems
  • 1.2 Symptomatic patients with end-organ damage hemochromatosis:
  • 1.3 Preferred regime: 1 unit of blood (about 473 mL or 1 pint) is removed per week
  • 1.4 Stop frequent phlebotomy when serum ferritin reaches 50-100 μg/L

2 Maintenance phlebotomy: When serum ferritin levels in the range of 50 to 100 ng/mL

  • 2.1 Preferred regime: Removing 1 unit of blood (about 473 mL or 1 pint) is removed per 2 months
  • 2.2 Alternative regime: Removing 1 unit of blood (about 473 mL or 1 pint) is removed per 4 months
  • 2.3 Check serum ferritin level every 10-12 phlebotomies

3 Dietary restrictions:

  • 3.1 Preferred regime: No restrictions.
  • 3.2 Alternative regime: avoid iron supplements, avoid vitamin C supplements, avoid alcohol completely

4 Non-HEF hemochromaosis:

  • 4.1 Preferred regime: 1 unit of blood (about 473 mL or 1 pint) is removed per week
  • 4.2 Alternative regime: In HIC is normal then follow dietary restrictions.

5 Secondary Iron Overload:

  • 5.1 Dyserythropoietic syndromes:
  • 5.1.1 Preferred regimen: Deferoxamine (Desferal) at a dose of 20-40 mg/kg body weight per day
  • 5.1.2 Alternative regime: Deferasirox (Exjade) given orally
  • 5.2 chronic hemolytic anemia:
  • 5.2.1 Preferred regimen: Deferoxamine at a dose of 20-40 mg/kg body weight per day
  • 5.2.2 Alternative regime: Deferasirox given orally
  • 5.3 Liver Biopsy
  • 5.3.1: Liver biopsy for evaluation not required.
  • 5.3.2: Consider follow-up liver biopsy to ascertain adequacy of iron removal.

Screening and diagnosis of hemochromatosis.WT, wild type; HII, histologic iron index; CII, chemical iron index; HH, hereditary hemochromatosis[5][6][7][8][9][10][11][12]

 
 
 
 
 
 
 
 
 
 
 
 
Serum Transferin Saturation
TS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<50% premenupasal females
<60% men, postmenupasal women
 
 
 
 
 
≥50% premenupasal females
≥60% men, postmenupasal women
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Repeat Transferin Saturation TS
2 Serum Feretin SF
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat testing every 5 year
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TS:<50% premenupasal females
TS: <60% men, postmenupasal women
SF: 20-250μg/L premenupasal females
SF: 10-120μg/L men, postmenupasal women
 
 
 
 
 
 
 
 
TS:≥50% premenupasal females
TS: ≥60% men, postmenupasal women
SF:>200 μg/L premenupasal females
SF:>300 μg/L men, postmenupasal women
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat TS and SF every 2-3 year
 
 
 
 
Serum Feretin<1000 μg/L
 
 
 
 
 
 
Serum Feretin>1000 μg/L
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Geno-typing
 
 
 
 
 
 
 
 
Liver biopsy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT/WT genotype
 
C282Y/WT genotype
 
 
 
C282Y/H63D genotype
 
C282Y/C282Y genotype
 
 
Histological iron index<0.15
Chemical iron index<2.0
 
Histological iron index>0.15
Chemical iron index>2.0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Secondray hemochromatosis
 
 
 
 
 
 
 
Phelebotomy to maintain Serum Feretin
 
 
 
 
Repeat TS and SF after 2-3 year
 
Phelebotomy to maintain Serum Feretin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screen family with Transferin Saturation & Serum Feretin if atypical HH suspected
 
 
 
 
 
 
 
Screen family with genotyping
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moniter Transferin Saturation & Serum Feretin in subclinical members

References

  1. Adams PC, Speechley M, Kertesz AE (1991). "Long-term survival analysis in hereditary hemochromatosis". Gastroenterology. 101 (2): 368–72. PMID 2065912.
  2. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G (1996). "Long-term survival in patients with hereditary hemochromatosis". Gastroenterology. 110 (4): 1107–19. PMID 8613000.
  3. Falize L, Guillygomarc'h A, Perrin M, Lainé F, Guyader D, Brissot P; et al. (2006). "Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases". Hepatology. 44 (2): 472–7. doi:10.1002/hep.21260. PMID 16871557.
  4. Adams PC, Deugnier Y, Moirand R, Brissot P (1997). "The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis". Hepatology. 25 (1): 162–6. doi:10.1002/hep.510250130. PMID 8985284.
  5. Bacon BR (2012). "Hemochromatosis: discovery of the HFE gene". Mo Med. 109 (2): 133–6. PMID 22675794.
  6. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma (2010). "Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements". J Gastroenterol Hepatol. 25 (4): 657–63. doi:10.1111/j.1440-1746.2009.06167.x. PMID 20492323.
  7. Adams PC (2015). "Epidemiology and diagnostic testing for hemochromatosis and iron overload". Int J Lab Hematol. 37 Suppl 1: 25–30. doi:10.1111/ijlh.12347. PMID 25976957.
  8. Salgia RJ, Brown K (2015). "Diagnosis and management of hereditary hemochromatosis". Clin Liver Dis. 19 (1): 187–98. doi:10.1016/j.cld.2014.09.011. PMID 25454304.
  9. Crownover BK, Covey CJ (2013). "Hereditary hemochromatosis". Am Fam Physician. 87 (3): 183–90. PMID 23418762.
  10. Adams PC, Barton JC, Guo H, Alter D, Speechley M (2015). "Serum ferritin is a biomarker for liver mortality in the Hemochromatosis and Iron Overload Screening Study". Ann Hepatol. 14 (3): 348–53. PMID 25864215.
  11. Adams PC, McLaren CE, Speechley M, McLaren GD, Barton JC, Eckfeldt JH (2013). "HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level <1000 µg/L". Can J Gastroenterol. 27 (7): 390–2. PMC 3956024. PMID 23862168.
  12. Lim A, Speechley M, Adams PC (2014). "Predicting C282Y homozygote genotype for hemochromatosis using serum ferritin and transferrin saturation values from 44,809 participants of the HEIRS study". Can J Gastroenterol Hepatol. 28 (9): 502–4. PMC 4205907. PMID 25314357.

Template:WH Template:WS